Wells Fargo analyst Mohit Bansal downgraded Karuna Therapeutics (KRTX) to Equal Weight from Overweight with a $330 price target after Bristol Myers (BMY) agreed to acquire Karuna for $330 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRTX:
- M & A News: Bristol-Myers (NYSE:BMY) to Acquire Karuna for $14B
- Karuna Therapeutics’ KarXT results in schizophrenia published in The Lancet
- Karuna Therapeutics initiated with bullish view at Citi, here’s why
- Karuna Therapeutics initiated with bullish view at Deutsche Bank, here’s why
- After AbbVie agrees to buy Cerevel, analysts weigh in on who may be next